| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.039 | 0.4 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.032 | 0.5 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.034 | 0.5 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.031 | 0.5 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.017 | 0.7 |